Oslo, Norway, 25 March 2026 - The Board of Directors of Lytix Biopharma AS (the "Company") (Euronext Growth Oslo: LYTIX) hereby calls for the Annual General Meeting to be held at Sandakerveien 138, 0484 Oslo, Norway, on 14 April 2026 at 13:00 hours (CEST).
The agenda for the Annual General Meeting includes, among other items, approval of the Company's annual report for 2025, election of board members, approval of remuneration to the Board of Directors and the Nomination Committee, and a new board authorization to increase the share capital in connection with the Company's option program.
The Board of Directors proposes that no dividend is distributed for the financial year 2025.
All documents related to the Annual General Meeting, including the notice, appendices, and the nomination committee's recommendation, are available on the Company's website: www.lytixbiopharma.com.
Shareholders wishing to attend the Annual General Meeting are requested to register their attendance or submit a proxy by 10 April 2026 at 13:00 (CEST).
For further information, please contact:
Gjest Breistein, CFO
E-mail: gjest.breistein@lytixbiopharma.com
Phone: +47 952 60 512
This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.
About Lytix Biopharma
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company developing novel immunotherapies based on oncolytic peptides that directly kill tumor cells and activate the immune system to target solid tumors. The company's lead product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule being evaluated across multiple cancer indications and treatment settings, both as monotherapy and in combination with immune checkpoint inhibitors.